Reports record profits, with the financial statements reflecting accelerated growth and high profitability, whilst maintaining financial stability
TEL AVIV, Israel , Aug. 11, 2025 /PRNewswire/ -- First...
60 finalists for SG60 milestone edition selected by an international panel of judges and visionary partnersFocus on empowering Urban Solutions and Sustainability to solve...
Washington, D.C., Aug. 09, 2025 (GLOBE NEWSWIRE) -- Ex-CIA strategist and economic advisor Jim Rickards is calling for “the return of American industry” — a silent revolution happening not in Washington, Wall Street, or Silicon Valley, but in the ground beneath America’s heartland.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against CTO Realty Growth, Inc. (“CTO” or the “Company”) (NYSE: CTO) and certain officers. The class action, filed in the United States District Court for the Middle District of Florida, and docketed under 25-cv-01516, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CTO securities between February 18, 2021 and June 24, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
SINGAPORE, Aug. 09, 2025 (GLOBE NEWSWIRE) -- With Bitcoin surpassing the $110,000 mark and stabilizing above that level, many analysts predict the cryptocurrency market will remain in a high-volatility phase for the foreseeable future. Holding spot positions may no longer yield quick profits in such a market. In response, BexBack Exchange is offering traders an unbeatable package to take advantage of these market conditions. The platform now features a 100% deposit bonus, a $50 welcome bonus for new users, and 100x leverage on cryptocurrency trading, giving investors incredible opportunities to maximize returns.
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –